« Return to News | CROs/Service Providers

Chiltern, Charles River Labs Partner on Early-phase Studies

Friday, February 26, 2010 06:54 AM

UK contract research organization (CRO) Chiltern International and preclinical CRO Charles River Laboratories are partnering to conduct and support early-phase radiolabelled studies.

The two companies will collaborate on studies using radiolabelled investigational products out of the CROs’ Europe-based facilities.

Chiltern’s early stage division—Chiltern Early Phase—in Dundee, Scotland, will perform the clinical aspects of the studies. The CRO has a 42-bed clinical pharmacology unit located in a UK National Health Service hospital and medical school. Charles River’s Metabolism and Pharmacokinetics facilty in Edinburgh includes a GMP clean room, licensed for the manufacture of radiolabelled drug products. The close proximity of the two laboratories enables the companies to turn around radioactivity data within 24 hours.

“This new partnership is an exciting collaboration. Charles River’s reputation is world-renowned for their conduct of studies using radiolabelled investigational products. Their extensive experience includes submission and review procedures for radiolabelled studies in man, including dosimetry calculations and submission to ARSAC,” said Chiltern CEO Glenn Kerkhof in a statement. “These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.